Explanipedia

Figure S3 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers Open

Kyung‐Don Kang, Stacie K. Totsch, Sam E. Gary, Li Nan, Rong Li , et al. · 2025

IHC staining of the ependymal lining for CD8+ cells and confirmation of CD8 depletion.

Figure S2 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers Open

Joshua D. Bernstock, Sam E. Gary, Abbey Rocco, Tina Etminan, Xiaosi Han , et al. · 2025

Toxicity from IVT oHSV in the left lateral ventricle and third and fourth ventricles at different time points.

Figure S7 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers Open

Kyung‐Don Kang, Stacie K. Totsch, Sam E. Gary, Li Nan, Tina Etminan , et al. · 2025

Interferon β (IFN β) levels over time in the CSF after a single 50 µg IVT dose of poly I:C or saline (N = 2 mice/group/time point).

Figure S6 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers Open

Kyung‐Don Kang, Stacie K. Totsch, Sam E. Gary, Li Nan, Rong Li , et al. · 2025

Time to recover baseline body weight in mice pretreated with low-dose oHSV prior to a standard treatment dose.

Figure S4 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers Open

Kyung‐Don Kang, Joshua D. Bernstock, Stacie K. Totsch, Sam E. Gary, Li Nan , et al. · 2025

Toxicity with repeated doses of IVT oHSV.

TMIC-119. Evaluating the Impact of Tumor-Secreted Fibronectin-1 on the Perivascular Niche (PVN) and Glioblastoma Malignancy Open

Mohammad Hashemi, Durgadevi Selvam, Divya Patel, C. Ryan Miller, Burt Nabors , et al. · 2025

Glioblastoma multiforme (GBM) is an aggressive brain tumor characterized by poor prognosis and frequent recurrence. The tumor microenvironment (TME) plays a crucial role in GBM progression, with extracellular matrix (ECM) components like F…

IMMU-83. CD4 T-cell reprogramming via oncolytic virotherapy enhances survival in glioblastoma Open

Jeffrey M Grimes, Sadashib Ghosh, James M. Markert, Jianmei W. Leavenworth · 2025

Glioblastoma (GBM) is the most prevalent and lethal primary malignant brain tumor in adults. Oncolytic viruses have emerged as a promising immunotherapy to treat GBM. However, the temporal impact on tumor cells and the tumor microenvironme…

IMG-133. System L amino acid ([F-18]FET) and hypoxia ([F-18]FMISO) PET/MRI to assess early response after completion of radiation therapy in high grade glioma Open

Kadir Gultekin, Ümmüşen Kaya Akça, J. Perry, Burt Nabors, Roxanne M. Lockhart , et al. · 2025

PURPOSE This ongoing study aims to determine 1) the frequency of PET positivity for high grade glioma (HGG) early after completion of radiation therapy (RT) using the amino acid [F-18]FET and 2) the relationships between [F-18]FET uptake a…

EXTH-113. Radiation synergizes with IL-12-expressing oncolytic herpes simplex virus to increase immune response in a murine model of high-grade glioma Open

Benjamin P. Lee, Yun Lü, Carlos Gallegos, Emily E. Helman, Shannon E. Lynch , et al. · 2025

Oncolytic herpes simplex viruses (oHSVs) are a promising treatment for high-grade glioma (HGG) and can be engineered to express immune activating transgenes, including IL-12. Prior work has demonstrated synergy between first-generation oHS…

Survival outcomes associated with antidepressant use in glioblastoma: a cohort study Open

Yifei Sun, Mohammad Hamo, Travis J. Atchley, James M. Markert, Burt Nabors , et al. · 2025

Frameless linac-based radiosurgery for benign intracranial tumors treated with HyperArc: analysis of tumor control and toxicity Open

Whitney S. Hotsinpiller, Evan Thomas, Ian Tsekouras, Richard A. Popple, Markus Bredel , et al. · 2025

Comparison of 3 vs 5 Fraction Single Isocenter Radiosurgery for Brain Metastases Open

Luke Moradi, Richard A. Popple, Roman Travis, Samuel Marcrom, Kristen Riley , et al. · 2025

Challenges and Opportunities in High-Grade Glioma Management and Imaging-Based Response Monitoring During Novel Immunotherapies Open

Carlos Gallegos, Benjamin P. Lee, Benjamin B. Kasten, Jack M. Rogers, Carlos Cárdenas , et al. · 2025

The highly heterogeneous and invasive nature characteristic of high-grade gliomas (HGG) has historically limited the efficacy of standard-of-care approaches, resulting in poor prognosis and treatment outcomes. Novel immunotherapies have sh…

HyperArc Automated Stereotactic Radiosurgery Planning Enables Accurate a Priori Fractionation Scheme Selection via Adherence to HyTEC Toxicity Thresholds Open

Joel A. Pogue, John B. Fiveash, R Cardan, Christopher Willey, Natalie Viscariello , et al. · 2025

The resulting models enabled accurate and precise prediction of target volumes/diameters, resulting in 3.6%, 4.8%, and 8.6% brain grade 1 to 3 toxicity rates, according to HyTEC toxicity estimates. Leveraging relative IDVs rather than pres…

Preoperative Stereotactic Radiosurgery for Brain Metastases: A Phase 1 Dose Escalation Study Demonstrating Reduced Leptomeningeal Disease Open

John M. Hoyle, James M. Markert, Kristen Riley, Christopher D. Willey, Samuel Marcrom , et al. · 2025

Preoperative SRS to 15 Gy is safe for tumors 2 to 6 cm and significantly reduces nLMD without compromising local control or OS. These findings support preoperative SRS as a viable treatment strategy and justify further investigation into o…

Survival Outcomes Associated with Antidepressant Use in Glioblastoma: A Cohort Study Open

Yifei Sun, Mohammad Hamo, Travis J. Atchley, James M. Markert, Burt Nabors , et al. · 2025

Frameless Linac-based Radiosurgery for Benign Intracranial Tumors Treated with HyperArc: Analysis of Tumor Control and Toxicity Open

Whitney S. Hotsinpiller, Evan Thomas, Ian Tsekouras, Richard A. Popple, Markus Bredel , et al. · 2025

Purpose: HyperArc™ (HA) automates both planning and delivery of single-isocenter VMAT radiosurgery (SRS) and was designed for complex multi-metastasis cases. The clinical effectiveness of treating benign intracranial tumors (BIT) with HA i…

IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunity Open

Upasana Sahu, Matthew P. Mullarkey, Sara A. Murphy, Joshua C. Anderson, Vasanta Putluri , et al. · 2025

Investigation of an oncolytic herpes simplex virus as a potential therapeutic agent for gastroenteropancreatic neuroendocrine neoplasms Open

Colin H. Quinn, Janet R. Julson, Michael H. Erwin, Hooper R. Markert, Larua V Bownes , et al. · 2025

The association of neighborhood-level deprivation with glioblastoma outcomes: a single center cohort study Open

Yifei Sun, Dagoberto Estévez-Ordoñez, Travis J. Atchley, Burt Nabors, James M. Markert · 2025

Comparison of 5-aminolevulinic acid and MMP-14 targeted peptide probes in preclinical models of GBM Open

Benjamin B. Kasten, Tingting Dai, Ke Jiang, Jennifer C. Clements, Kaixiang Zhou , et al. · 2025

Rationale: Developing novel pre-operative and intraoperative imaging approaches for glioblastoma multiforme (GBM) could aid therapeutic intervention while sparing healthy normal brain, which remains a significant clinical challenge.…

Oncolytic reprogramming of tumor microenvironment shapes CD4 T-cell memory via the IL6ra-Bcl6 axis for targeted control of glioblastoma Open

Jeffrey M Grimes, Sadashib Ghosh, Shaista Manzoor, Li Xin Li, Monica M. Moran , et al. · 2025

The Association of Neighborhood-Level Deprivation with Glioblastoma Outcomes: A Single Center Cohort Study Open

Yifei Sun, Dagoberto Estévez-Ordoñez, Travis J. Atchley, Burt Nabors, James M. Markert · 2025

Purpose Glioblastoma is the most common primary brain malignancy. Though literature has suggested the association of glioblastoma outcomes and socioeconomic status, there is limited evidence regarding the association of neighborhood-level …

Herpes Simplex Oncolytic Viral Therapy for Malignant Glioma and Mechanisms of Delivery Open

Nicholas Erickson, Mihaela Stavarache, T. Ibrahim, Michael G. Kaplitt, James M. Markert · 2025

Assessment of Local and Regional Control in High-Risk Atypical (WHO Grade 2) Meningiomas Receiving Stereotactic Fractionated Radiosurgery Open

Roman Travis, Marie E. Taylor, Christopher Willey, Markus Bredel, Kristen Riley , et al. · 2025

The effect of antidepressants on glioblastoma survival: A systematic review and meta-analysis Open

Yifei Sun, Mohammad Hamo, Travis J. Atchley, Burt Nabors, James M. Markert , et al. · 2025

Symptoms of depression are highly prevalent among patients with glioblastoma and have been associated with poor outcomes. In addition to managing depression symptoms, preclinical and clinical studies suggest that antidepressants may inhibi…

999 Oncolytic virotherapy-mediated intratumoral IL-12 and its impact on immune cell function: insights from spectral flow cytometry Open

Yeaseul Kim, Uksha Saini, Do‐Yeon Kim, Idoia Aguirre, Jack Hedberg , et al. · 2024

Oncolytic virotherapy augments self-maintaining natural killer cell line cytotoxicity against neuroblastoma Open

Colin H. Quinn, Janet R. Julson, Hooper R. Markert, Nazia Nazam, Swatika Butey , et al. · 2024

IMMU-19. COMBINATION IMMUNOTHERAPY SEQUENCE MATTERS: VACCINE PRIOR TO ONCOLYTIC HSV VIROTHERAPY ENHANCES TUMOR-SPECIFIC T CELL RESPONSES AND EFFICACY Open

Kyung‐Don Kang, Stacie K. Totsch, Andrew S. Ishizuka, Sam E. Gary, Abbey Rocco , et al. · 2024

BACKGROUND Safety and preliminary efficacy have been demonstrated with intratumoral oncolytic, engineered HSV immunotherapy; however, few responses have been durable, suggesting that augmented, prolonged anti-tumor T cell responses are lik…

Enhanced IL-12 transgene expression improves oncolytic viroimmunotherapy Open

Yeaseul Kim, Uksha Saini, Do‐Yeon Kim, Ilse Hernandez-Aguirre, Jack Hedberg , et al. · 2024

Introduction Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas with unacceptably low cure rates occurring often in patients with neurofibromatosis 1 defects. To investigate oncolytic Herpes Simplex Virus (oHSV) as a…

James M. Markert YOU? Author Swipe